Posted by Michael Wonder on 22 Oct 2025
Myosin Therapeutics receives FDA fast track designation for MT-125 in glioblastoma
22 October 2025 - Myosin Therapeutics today announced that the US FDA has granted fast track designation to MT-125 for the treatment of glioblastoma.
MT-125 is a first in class dual inhibitor of non-muscle myosin IIA and IIB.
